Aethlon Medical IncAEMD
Price (close)
$6.28
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$6.9M
Dividend yield
—
1-year total return
-83.7%
Net margin
—
Revenue growth
—
Debt / equity
—
What Aethlon Medical Inc does.
focused on developing the Hemopurifier® (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet
needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles
(EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $659,104 | $294,165 | $574,245 | $0 | — | — |
| Net income | -$7.9M | -$10.4M | -$12.0M | -$12.2M | -$13.4M | -$7.2M |
| Free cash flow | -$6.8M | -$10.1M | -$11.4M | -$10.4M | -$7.6M | -$7.0M |
More on AEMD.
- Aethlon Medical Inc summary
- Aethlon Medical Inc financial statements
- Aethlon Medical Inc key metrics
- Aethlon Medical Inc health scores and style box
- Aethlon Medical Inc earnings
- Aethlon Medical Inc dividends
- Aethlon Medical Inc valuation
- Aethlon Medical Inc ownership and insiders
- Aethlon Medical Inc peers
Figures from Aethlon Medical Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.